Genprex Inc (GNPX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.48 (+0.58%), Market cap $0.01B, 52-week low–high $0.14 ~ $11.50.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. It also develops REQORSA Gene Therapy in Mesothelioma, Ras Inhibitor Resistan
Financial statements, price targets, institutional (13F) holdings and related news for Genprex Inc are updated in real time on BlackAll Trade.
Genprex Inc trades at $3.48 (+0.58%). Real-time quotes and charts are available on BlackAll Trade.
Genprex Inc has a market cap of about $0.01B.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting gene